# Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

> **NCT00088998** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 46 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00088998
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-08
- **Final completion:** 2010-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2016-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088998, "Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00088998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*